Neue Arzneimittel

  • Uwe Fricke
  • Ulrich Schwabe

Zusammenfassung

Die Verordnungen neuer Arzneimittel haben in den vergangenen Jahren überdurchschnittlich stark zugenommen. Hauptgrund für diese Entwicklung dürfte der stetige Aufwärtstrend der neuen Wirkstoffe sein, die jährlich in Deutschland auf den Markt kommen (Abbildung 2.1). Die zunehmende therapeutische Bedeutung der Neueinführungen hat uns dazu veranlaßt, die neuen Wirkstoffe des Jahres 2000 und ihre Verordnungsentwicklung ausführlicher zu besprechen und in einem eigenen Kapitel darzustellen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Al-Salman J., Arjomand H., Kemp D.G., Mittal M. (2000): Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann. Intern. Med. 132: 121–124.PubMedGoogle Scholar
  2. American Thoracic Society (2000): Guidelines for methacholine and exercise challenge testing - 1999. Am. J. Respir. Crit. Care Med. 161: 309–329.Google Scholar
  3. Arzneimittelkommission der deutschen Ärzteschaft (2000): Vorsicht bei der Verordnung von Bupropion zur Raucherentwöhnung. Dtsch. Ärztebl. 97: A–863.Google Scholar
  4. Arzneimittelkommission der deutschen Apotheker (2000): Etanercept (Enbrel®): Demyelisierung des ZNS. Pharm. Ztg. 145: 3786.Google Scholar
  5. Arzneimittelkommission der deutschen Apotheker (2001): Levacetylmethadol (Orlaam®). Pharm. Ztg. 146: 1367.Google Scholar
  6. Banderali G., Riva E., Fiocchi A., Cordaro C.I., Giovannini M. (1995): Efficacy and to-lerability of levodropropizine and dropropizine in children with non-productive cough. J. Int. Med. Res. 23:175–183.PubMedGoogle Scholar
  7. Bariffi F., Tranfa C., Vatrella A., Ponticiello A. (1992): Protective effect of levodropropizine against cough induced by inhalation of nebulized distilled water in patients with obstructive lung disease. Drugs Exp. Clin. Res. 18:113–118.PubMedGoogle Scholar
  8. Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C. et al. (2000): A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343: 1586–1593.PubMedCrossRefGoogle Scholar
  9. Birnstiel S., Wulfert E., Beck S.G. (1997): Levetiracetam (ucb L059) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission. Naunyn-Schmiedebergs Arch. Phamacol. 356: 611–618.CrossRefGoogle Scholar
  10. Bleyer A.J., Burke S.K., Dillon M., Garrett B., Kant K.S., Lynch D. et al. (1999): A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am. J. Kidney Dis. 33: 694–701.PubMedCrossRefGoogle Scholar
  11. Bolli G.B., Owens D.R. (2000): Insulin glargine. Lancet 356:443–445.PubMedCrossRefGoogle Scholar
  12. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B. et al. for the VIGOR Study Group (2000): Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 343:1520–1528.PubMedCrossRefGoogle Scholar
  13. Brusilow S.W., Maestri N.E. (1996): Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv. Pediatr. 43:127–170.PubMedGoogle Scholar
  14. Burstein H.J., Kuter I., Richardson P.G. et al. (2000): Herceptin and vinorelbine for HER2-positive metastatic breast cancer: a phase II study. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2000: 392a.Google Scholar
  15. Catena E., Daffonchio L. (1997): Efficacy and tolerability of levodropropizine in adult patients with non-productive cough. Comparison with dextromethorphan. Pulm. Pharmacol. Ther. 10: 89–96.PubMedCrossRefGoogle Scholar
  16. Cereghino J.J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L.J., Leppik I. (2000): Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55: 236–242.PubMedCrossRefGoogle Scholar
  17. Chan C.-C., Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D. et al. (1999): Rofecoxib [Vioxx, MK-0966; 4-(4’-Methylsulfonylphenyl)-3-phenyl-2-(5H)-fu-ranone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.J. Pharmacol. Exp. Ther. 290: 551–560.PubMedGoogle Scholar
  18. Clemett D., Goa K.L. (2000): Celecoxib. A review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 59: 957–980.PubMedCrossRefGoogle Scholar
  19. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L. et al. (1999): Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17: 2639–2648.PubMedGoogle Scholar
  20. Crandall C. (2001): Risedronate. A clinical review. Arch Intern. Med. 161: 353–360.CrossRefGoogle Scholar
  21. Croxatto H.B., Makarainen L. (1998): The pharmacodynamics and efficacy of Im-planon. An overview of the data. Contraception 58 (Suppl. 6): 91S–97S.PubMedCrossRefGoogle Scholar
  22. Croxatto H.B., Urbancsek J., Massai R., Bennink H.C., van Beek A. and the Implanon® Study Group (1999): A multicentre efficacy and safety study of the single contraceptive implant Implanon®. Hum. Reprod. 14: 976–981.PubMedCrossRefGoogle Scholar
  23. De la Garza R., Johanson C.E. (1987): Discriminative stimulus properties of intragastrically administered d-amphetamine and pentobarbital in rhesus monkeys. J. Pharmacol. Exp. Ther. 243: 955–962.PubMedGoogle Scholar
  24. Dobson R. (2001): Antismoking drug comes under scrutiny after deaths. Brit. Med. J. 322: 452.PubMedCrossRefGoogle Scholar
  25. Dooley M., Plosker G.L. (2000): Levetiracetam. A review of its adjunctive use in the management of partial onset seizures. Drugs 60: 871–893.PubMedCrossRefGoogle Scholar
  26. Einhorn D., Rendell M., Rosenzweig J., Egan J.W., Mathisen A.L., Schneider R.L. for the Piaglitazone 027 Study Group (2000): Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin. Ther. 22:1395–1409.PubMedCrossRefGoogle Scholar
  27. Emery P., Zeidler H., Kvien T.K., Guslandi M., Naudin R., Stead H. et al. (1999): Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 354:2106–2111.PubMedCrossRefGoogle Scholar
  28. European Agency for the Evaluation of Medicinal Products (EMEA) (1999): Regranex, European Public Assessment Report (EPAR), 29 March 1999.Google Scholar
  29. European Agency for the Evaluation of Medicinal Products (EMEA) (2000a): Trac-tocile, European Public Assessment Report (EPAR), 20 January 2000.Google Scholar
  30. European Agency for the Evaluation of Medicinal Products (EMEA) (2000b): Enbrel, European Public Assessment Report (EPAR), 3 February 2000.Google Scholar
  31. European Agency for the Evaluation of Medicinal Products (EMEA) (2000c): EMEA public statement on etanercept (Enbrel) - serious hematological reactions -, The European Agency for the Evaluation of Medicinal Products, 3 October 2000.Google Scholar
  32. European Agency for the Evaluation of Medicinal Products (EMEA) (2000d): Draft concept paper on the development of a CPMP points to consider document on the non-clinical assessment of the carcinogenic potential of human insulin analogues. 12 April 2000.Google Scholar
  33. European Agency for the Evaluation of Medicinal Products (EMEA) (2000e): Avandia, European Public Assessment Report (EPAR), 11 July 2000.Google Scholar
  34. European Agency for the Evaluation of Medicinal Products (EMEA) (2000f): Renagel, European Public Assessment Report (EPAR), 28 January 2000.Google Scholar
  35. Feldman A.M., Lorell B.H., Reis S.E. (2000): Trastuzumab in the treatment of meta-static breast cancer: anticancer therapy versus cardiotoxicity. Circulation 102: 272–274.PubMedCrossRefGoogle Scholar
  36. Foidart J.-M., Wuttke W., Bouw G.M., Gerlinger C., Heithecker R. (2000): A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur. J. Contracept. Reproduct. Health Care 5:124–134.CrossRefGoogle Scholar
  37. Fonseca V., Rosenstock J., Patwardhan R., Salzman A. (2000): Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. JAMA 283:1695–1702.PubMedCrossRefGoogle Scholar
  38. Forman L.M., Simmons D.A., Diamond R.H. (2000): Hepatic failure in a patient taking rosiglitazone. Ann. Intern. Med. 132:118–121.PubMedGoogle Scholar
  39. Fornier M., Esteva F.J., Seidman A.D. (2000): Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin. Oncol. 27 (Suppl. 11): 38–45.PubMedGoogle Scholar
  40. Fricke U. (2000): Neue Arzneimittel - Ein Überblick. Therapiesymposium 2000. Arzneimittelkommission der deutschen Ärzteschaft, Frankfurt am Main.Google Scholar
  41. Friedrich J.M., Sergeev P.V., Shimanovskii K.L. (1995): Vergleichende Untersuchung zur Freisetzung von Histamin aus basophilen humanen Granulozyten bei ionischen und nicht-ionischen Kontrastmitteln. Radiologe 35: S24.Google Scholar
  42. Gajwani P., Pozuelo L., Tesar G.E. (2000): QT interval prolongation associated with quetiapine (Seroquel) overdose. Psychosomatics 41: 63–65.PubMedCrossRefGoogle Scholar
  43. Gale E.A.M. (2001): Lessons from the glitazones: a story of drug development. Lancet 357:1870–1875.PubMedCrossRefGoogle Scholar
  44. Gillies P.S., Figgitt D.P., Lamb H.M. (2000): Insulin glargine. Drugs 59: 253–260.PubMedCrossRefGoogle Scholar
  45. Glue P., Fang J.W., Rouzier-Panis R., Raffanel C., Sabo R., Gupta S.K. et al. for the Hepatitis C Intervention Therapy Group (2000a): Pegylyated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin. Pharmacol. Ther. 68: 556–567.PubMedCrossRefGoogle Scholar
  46. Glue P., Rouzier-Panis R., Raffanel C., Sabo R., Gupta S.K., Salfi M. et al. for the Hepatitis C Intervention Therapy Group (2000b): A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 32: 647–653.PubMedCrossRefGoogle Scholar
  47. Goss P.E., Strasser K. (2001): Aromatase inhibitors in the treatment and prevention of breast cancer. J. Clin. Oncol. 19: 881–894.PubMedGoogle Scholar
  48. Grant S.M., Faulds D. (1992): Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 43: 873–888.PubMedCrossRefGoogle Scholar
  49. Harrison C. (2001): Bupropion for smokers. Bupropion may not be as good as editorial implies. Brit. Med. J. 322: 431.PubMedCrossRefGoogle Scholar
  50. Hassan-Alin M., Andersson T., Bredberg E., Röhss K. (2000): Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur. J. Clin. Pharmacol. 56: 665–670.PubMedCrossRefGoogle Scholar
  51. Heinemann L., Linkeschova R., Rave K., Hompesch B., Sedlak M., Heise T. (2000): Time-action profile of the long-actinig insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23: 644–649.PubMedCrossRefGoogle Scholar
  52. Horton J. (2001): HER2 and trastuzumab in breast cancer. Cancer Control 8: 103–110.PubMedGoogle Scholar
  53. Jackson L.M., Hawkey C.J. (2000): COX-2 selective nonsteroidal anti-inflammatory drugs. Do they really offer any advantages? Drugs 59:1207–1216.PubMedCrossRefGoogle Scholar
  54. Jauch A., Fsadni M., Gamba G. (1999): Meta-analysis of six clinical phase III studies comparing lomefloxacin 0.3% eye drops twice daily to five standard antibiotics in patients with acute bacterial conjunctivitis. Graefe’s Arch. Clin. Exp. Ophthalmol. 237: 705–713.CrossRefGoogle Scholar
  55. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R. et al. (1999): A controlled trial of sustained-release Bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 340: 685–691.CrossRefGoogle Scholar
  56. Kahrilas P.J., Falk G.W., Johnson D.A., Schmitt C, Collins D.W., Whipple J. et al. (2000): Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment. Pharmacol. Ther. 14: 1249–1258.PubMedCrossRefGoogle Scholar
  57. Kasper S., Müller-Spahn F. (2000): Review of quetiapine and its clinical applications in schizophrenia. Expert. Opin. Pharmacother. 1: 783–801.PubMedCrossRefGoogle Scholar
  58. Kaufmann M., Bajetta E., Dirix L.Y., Fein L.E., Jones S.E., Zilembo N. et al. (2000): Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J. Clin. Oncol. 18:1399–1411.PubMedGoogle Scholar
  59. King A.B. (2000): A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 23: 557.PubMedCrossRefGoogle Scholar
  60. Kinnell H.G. (2001): Bupropion for smokers. Drug is almost identical in structure to diethylpropion, a controlled drug. N. Engl. J. Med. 340: 431.Google Scholar
  61. Klitgaard H., Matagne A., Gobert J., Wulfert E. (2000): Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol.353:191–206.CrossRefGoogle Scholar
  62. Konecny G., Untch M., Pegram M. (1999): Herceptin in der Therapie des metasta-sierten Mammakarzinoms. Gynäkologe 32: 624–631.Google Scholar
  63. Krattenmacher R. (2000): Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62: 29–38.PubMedCrossRefGoogle Scholar
  64. Kurtzhals P., Schäffer L., Sørensen A., Kristensen C., Jonassen L, Schmid C., Trüb T.(2000): Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49: 999–1005.PubMedCrossRefGoogle Scholar
  65. Kwan A.L., Meiners A.P., van Grootheest A.C., Lekkerkerker J.F. (2001): Risk of convulsions due to the use of bupropion as an aid for smoking cessation. Ned.Tijdschr. Geneeskd. 145: 277–278.PubMedGoogle Scholar
  66. Lamb H.M., Figgitt D.P., Faulds D. (1999): Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs 58:1061–1097.PubMedCrossRefGoogle Scholar
  67. Lanza F.L., Hunt R.H., Thomson A.B., Provenza J.M., Blank M.A. (2000a): Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 119: 631–638.PubMedCrossRefGoogle Scholar
  68. Lanza F., Schwartz H., Sahba B., Malaty H.M., Musliner T., Reyes R., Quan H., Graham D.Y. (2000b): An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am. J. Gastroenterol. 95: 3112–3117.PubMedCrossRefGoogle Scholar
  69. Lemke A.J., Sander B., Balzer T., Geens V., Hosten N., Felix R. (1997): Sicherheit und Nutzen von Gadobutrol bei Patienten mit zerebralen Tumoren (Phase-III-Studie).Röfo. Fortschr. Geb. Röntgenstr. Neue Bildgeb. Verfahr. 167: 591–598.CrossRefGoogle Scholar
  70. Lovell D.J., Giannini E.H., Reiff A., Cawkwell G.D., Silverman E.D., Nocton J.J. et al.(2000): Etanercept in children with polyarticular juvenile rheumatoid arthritis.N. Engl. J. Med. 342: 763–769.PubMedCrossRefGoogle Scholar
  71. Maestri N.E., Brusilow S.W., Clissold D.B., Bassett S.S. (1996): Long-term treatment of girls with ornithine transcarbamylase deficiency. N. Engl. J. Med. 335:855–859.PubMedCrossRefGoogle Scholar
  72. Maul H., Winkler M., Rath W. (2000): Klinische Erfahrungen mit Atosiban. Neuer Oxytocin-Rezeptorantagonist zur Wehenhemmung. Dtsch. Ärztebl. 97: A3427–A3432.Google Scholar
  73. McClellan K.J., Jarvis B. (2000): Lercanidipine. A review of its use in hypertension.Drugs 60:1123–1140.PubMedCrossRefGoogle Scholar
  74. McKee P.J., Blacklaw J., Forrest G., Gillham R.A., Walker S.M., Connelly D., Brodie M.J. (1994): A double-blind, placebo-controlled interaction study between ox-carbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br. J. Clin. Pharmacol. 37: 27–32.PubMedCrossRefGoogle Scholar
  75. Moreland L.W., Schiff M.H., Baumgartner S.W., Tindall E. A., Fleischmann R.M., Bulpitt K.J. et al. (1999): Etanercept therapy in rheumatoid arthritis. Ann. Intern. Med. 130:478–486.PubMedGoogle Scholar
  76. Noble S., Goa K.L. (2000): Amprenavir: a review of its clinical potential in patients with HIV infection. Drugs 60:1383–1410.PubMedCrossRefGoogle Scholar
  77. Oelkers W., Heimerhorst F.M., Wuttke W., Heithecker R. (2000): Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol. Endocrinol. 14: 204–213.PubMedCrossRefGoogle Scholar
  78. Parulkar A.A., Pendergrass M.L., Granda-Ayala R., Lee T.R., Fonseca V.A. (2001): Nonhypoglycemic effects of thiazolidinediones. Ann. Intern. Med. 134: 61–71.PubMedGoogle Scholar
  79. Peterson W.L., Cryer B. (1999): COX-1-sparing NSAIDs - is the enthusiasm justified? JAMA 282:1961–1963.PubMedCrossRefGoogle Scholar
  80. Ravinuthala R.S., Nori U. (2000): Rosiglitazone toxicity. Ann. Intern. Med. 133: 658.PubMedGoogle Scholar
  81. Reutter H., Bort S., Jung M.F., Klyscz T., Schippert W., Zuder D., Jünger M. (1999): Fragliche Wirksamkeit autologer thrombozytärer Wachstumsfaktoren (PDWHF) in der Behandlung venöser Beinulzera. Hautarzt 50: 859–865.PubMedCrossRefGoogle Scholar
  82. Rush C.R., Kollins S.H., Pazzaglia P.J. (1998): Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-ampheta-mine-trained humans. Exp. Clin. Psychopharmacol. 6: 32–44.PubMedCrossRefGoogle Scholar
  83. Sall K., the Brinzolamide Primary Therapy Study Group (2000): The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt®) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv. Ophthalmol. 44 (Suppl. 2): 163–168.Google Scholar
  84. Seymour H.E., Worsley A., Smith J.M., Thomas S.H.L. (2001): Anti-TNF agents for rheumatoid arthritis. Br. J. Clin. Pharmacol. 51: 201–208.PubMedCrossRefGoogle Scholar
  85. Shiffman S., Johnston J.A., Khayrallah M., Elash C.A., Gwaltney C.J., Paty J.A. et al. (2000): The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology 148: 33–40.PubMedCrossRefGoogle Scholar
  86. Simon L.S., Weaver A.L., Graham D.Y., Kivitz A.J., Lipsky P.E., Hubbard R.C. et al. (1999): Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial. JAMA 282:1921–1928.Google Scholar
  87. Smiell J.M., Wieman J., Steed D.L., Perry B.H., Sampson A.R., Schwab B.H. (1999): Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Rep. Reg. 7: 335–346.CrossRefGoogle Scholar
  88. Spencer C.M., Faulds D. (2000): Esomeprazole. Drugs 60: 321–329.PubMedCrossRefGoogle Scholar
  89. Srisurapanont M., Disayavanish C., Taimkaew K. (2000): Quetiapine for schizophrenia. Cochrane Database Syst. Rev. 3: CD000967.PubMedGoogle Scholar
  90. Staks T., Schuhmann-Giampieri G., Frenzel T., Weinmann H.J., Lange L., Platzek J. (1994): Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest. Radiol. 29: 709–715.PubMedCrossRefGoogle Scholar
  91. TAP Study Group (1999): Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials - TAP Report 1. Arch. Ophthalmol. 117: 1329–1345.Google Scholar
  92. TAP Study Group (2001): Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials - TAP Report 2. Arch. Ophthalmol. 119:198–207.Google Scholar
  93. The European and Middle East Orgalutran Study Group (2001): Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist troptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum. Reprod. 16: 644–651.CrossRefGoogle Scholar
  94. The Worldwide Atosiban versus Beta-agonists Study Group (2001): Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. BJOG 108:133–142.CrossRefGoogle Scholar
  95. Wiendl H., Neuhaus O., Kappos L., Hohlfeld R. (2000): Multiple Sklerose. Aktuelle Übersicht zu fehlgeschlagenen und abgebrochenen Therapiestudien. Nervenarzt 71: 597–610.PubMedCrossRefGoogle Scholar
  96. Wolffenbuttel B.H., Gomis R., Squatrito S., Jones N.P., Patwardhan R.N. (2000): Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabet. Med. 17:40–47.PubMedCrossRefGoogle Scholar
  97. Yki-Järvinen H., Dresler A., Ziemen M., the HOE 901/3002 Study Group (2000): Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargin compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 23:1130–1136.PubMedCrossRefGoogle Scholar
  98. Zung W.W. (1983): Review of placebo-controlled trials with bupropion. J. Clin. Psychiatry 44: 104–114.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • Uwe Fricke
  • Ulrich Schwabe

There are no affiliations available

Personalised recommendations